Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o1/o7/96 \ \ Origin: Appendix 5 \ \ Amended o1/o7/98, o1/o9/99, o1/o7/oo, 30/o9/o1, 11/o3/o2, o1/o1/o3, 24/10/o5, o1/o8/12, o4/o3/13$ 

Name of entity			
ATCOR MEDICAL HOLDINGS LIMITED			
ABN			
81 113 :	252 234		
We (the entity) give ASX the following information.			
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).			
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Fully paid ordinary shares	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	17,793,393	
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	As per other ordinary shares	

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$0.18
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Capital raised from the rights issue, and from the placement announced on 17 June 2015 will be used as follows:  • \$1.8 mill to prepare AtCor for launch into CPT1; hiring additional sales & marketing staff, consulting services and other activities to expand in USA following positive coding decision.  • \$0.8 mill for product development activities  • \$2.6 mill for other working capital purposes
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	N/a
6b	The date the security holder resolution under rule 7.1A was passed	
6c	Number of *securities issued without security holder approval under rule 7.1	

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A		
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)		
6f	Number of *securities issued under an exception in rule 7.2		
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.		
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements		
7	<sup>+</sup> Issue dates	23 July 2015	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.		
	eross reference, term 33 of Appendix 32.		
		Number	<sup>+</sup> Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	198,673,039	Fully paid ordinary

<sup>+</sup> See chapter 19 for defined terms.

		Number	<sup>+</sup> Class
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	19,078,333	Unquoted options
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/a	
Part	2 - Pro rata issue		
11	Is security holder approval required?	No	
12	Is the issue renounceable or non-renounceable?	Non-renounceable	
13	Ratio in which the *securities will be offered	1 ordinary share for every 10 ordinary shares held	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Fully paid ordinary shares	
15	<sup>+</sup> Record date to determine entitlements	30 June 2015	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/a	
17	Policy for deciding entitlements in relation to fractions	Where fractions arise in the calculation of entitlements they will be rounded up to the nearest whole number of shares	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	All countries except Australia and New Zealand	
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.		
19	Closing date for receipt of acceptances or renunciations	16 July 2015	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 4 04/03/2013

20	Names of any underwriters	Taylor Collison Limited
21	Amount of any underwriting fee or commission	An underwriting fee of 5.0% of the proceeds of the rights issue, a management fee of 1.0% of the rights issue.
22	Names of any brokers to the issue	N/a
23	Fee or commission payable to the broker to the issue	N/a
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/a
25	If the issue is contingent on security holders' approval, the date of the meeting	N/a
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	1 July 2015
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	23 June 2015
28	Date rights trading will begin (if applicable)	N/a
29	Date rights trading will end (if applicable)	N/a
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/a
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/a

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by nrough a broker)?	N/a
33	<sup>+</sup> Issue	e date	23 July 2015
		uotation of securitie	<b>S</b> oplying for quotation of securities
34	Type (tick o	of *securities one)	
(a)		*Securities described in Part	1
(b)		*	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entiti	es tha	t have ticked box 34(a)	
Addit	ional	securities forming a new	class of securities
Tick to docum		e you are providing the informat	ion or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36			securities, a distribution schedule of the additional umber of holders in the categories
37		A copy of any trust deed for	the additional <sup>+</sup> securities

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Entities that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of		
	another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	<sup>+</sup> Class

<sup>+</sup> See chapter 19 for defined terms.

## **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Director/Company secretary)

Print name: Peter Manley

== == == ==

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.